NR3C1 and non-small cell lung carcinoma: Delving deeper into the GR-dependent drug resistance mechanisms and developing therapeutic strategies to counteract them will allow clinical oncologists to safely and effectively continue using synthetic glucocorticoids to alleviate chemotherapy-induced side effects, as well as improving the clinical outcome of NSCLC patients receiving chemotherapy together with glucocorticoids.